CollPlant Biotechnologies Ltd.
PublicCollPlant Biotechnologies Ltd. is now publicly traded
The data on this page reflects CollPlant Biotechnologies Ltd.'s private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Last Round
Private Placement
Jul 6, 2026
Total Funding Raised
$10.4M
Company Overview
CollPlant Biotechnologies Ltd. operates in Healthcare and is based in Israel. It has raised $10.4M.
CollPlant Biotechnologies Ltd. is a regenerative and aesthetic medicine company that develops products based on its proprietary recombinant human collagen (rhCollagen) for 3D bioprinting of tissues and organs, medical aesthetics, and advanced wound care.
Sector
Healthcare
AI Layer
Non-AI
CollPlant Biotechnologies Ltd. Comparables
Compare CollPlant Biotechnologies Ltd. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Tempo Therapeutics, Inc. | 74% | |
| Spiber Technologies AB | 66% | |
| ST1 Co., Ltd. | 58% |
For institutional investors. Book with your work email.
CollPlant Biotechnologies Ltd. Funding Rounds
Historical fundraising activity
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- invests_intoSep 3, 2026
At closing, CollPlant Biotechnologies Ltd., among others, invested $5M in LightSolver Ltd. and issued upfront ordinary shares and pre-funded warrants to support its commercialization, strategic partnerships, and long-term technology roadmap.
- acquiresAug 31, 2026
Collplant Limited acquired LightSolver Ltd. for $5M on Aug 31st '26.
For institutional investors. Book with your work email.
CollPlant Biotechnologies Ltd. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.